Adamed Pharma strengthens its manufacturing presence in Europe through the acquisition of a production facility in Spain

Adamed Pharma, a Polish family-owned pharmaceutical and biotechnology company, has announced that it has entered into a preliminary agreement with Sanofi regarding the acquisition of a manufacturing facility located in Riells i Viabrea, Spain. Completion of the transaction is planned for the second quarter of 2026.

A strategic step in long-term international development

The acquisition of the Riells facility is part of Adamed’s long-term international growth strategy. The company has been consistently investing in modern manufacturing capacities, as well as in the development of logistics and technologies.

Building on an established industrial site

The Riells facility has a history of more than 50 years, specializes in the production of solid oral dosage forms, and employs more than 200 highly qualified staff. Adamed intends to maintain the current level of employment and existing working conditions, while gradually expanding the site’s manufacturing and distribution capabilities, strengthening its role in international markets.

“Our intention is to build on what already exists in Riells: the people, the expertise, and the manufacturing strength of this site. We see Riells as a long-term industrial project and we plan to invest so that the facility can continue to grow and play a significant role in the years to come”, said Małgorzata Adamkiewicz, MD, PhD, President of the Supervisory Board and Co-owner of Adamed Pharma S.A.

Portfolio evolution and industrial transformation at Sanofi

Sanofi’s decision to divest the facility stems from the implementation of the company’s global strategy, focused on the development of innovative therapies in key areas, particularly immunology. Sanofi is adapting its manufacturing network to future research and development needs and its new product portfolio.

“Riells is a strong industrial site with a long history and deeply committed teams. We are confident that under Adamed’s leadership the facility will continue to uphold the highest standards of quality and safety, while investing in new technologies that will strengthen its manufacturing and distribution capabilities”, said Marzia Bove, Head of Manufacturing & Supply Cluster (General Medicines) at Sanofi.

As part of the manufacturing site acquisition, Adamed also entered into a cooperation agreement under which it will continue manufacturing Sanofi’s products at the Riells facility over the next years. Product ownership and commercialization will remain with Sanofi, with no impact on patients, healthcare professionals, or supply continuity. At the same time, Adamed will introduce its own products into manufacturing at the site.